A combination of rye pollen and phytosterol marketed by Pharmactive as Plasys300 was associated with reductions in nocturia, in a consumer study the brand conducted.
 
Nocturia is often a sign of bladder obstruction caused by an enlarged prostate, also known as benign prostate hyperplasia (BPH), a common condition that effects men as they age. Approximately 40% of men in their 50s have BPH, which increases to 90% in men over the age of 80. Frequent nocturnal urination is one of the key symptoms, and incomplete bladder emptying, leakage, and chronic discomfort occurs in many cases.
 
Plasys300 is a composition of rye pollen enhanced with phytosterols, chiefly beta-sitosterol. It is standardized to at least 50% phytosterols and to less than 1% essential amino acids.
 
The eight-week consumer study recruited 50 men between the ages of 40 and 60 contenting with nocturia, in which volunteers consumed one 300 mg capsule of the ingredient daily and conducted online self-assessments.
 
“Nocturia is known to disrupt sleep quality and negatively impact overall quality of life,” said María Inés Morán Valero, PhD, senior scientific researcher and scientific studies manager at Pharmactive. “We found that men have very specific and clear expectations for nocturia supplements. They want a product that effectively reduces the urge to urinate at night, minimizing nighttime awakenings so they can sleep more soundly and feel less fatigued. They also expressed a preference for natural ingredients that have been tested by fellow consumers for safety, efficacy, and reliability.”
 
At the conclusion of the study, 88% of the participants reported meaningful reductions in the urge to urinate, and 90% reported fewer nighttime awakenings. More than 80% of the subjects noted that they enjoyed better sleep quality as well as improvements in overall well-being and quality of life.
 
Beta-sitosterol has been determined in past research to inhibit excess testosterone production, which is associated with prostate enlargement, the company noted. Combined with essential amino acids from rye pollen, the finished ingredient was evidenced in prior in vitro research to exhibit anti-oxidant and inflammatory modulating activity. The prior research is believed to support prostate health through several mechanisms including inhibition of aromatase and 5-alpha-reductase concentrations in the prostate; balancing cellular growth factors that play roles in prostate function; and preventing overstimulation of certain prostate receptors.
 
“The results of the current study are very promising, especially the significant improvements reported in symptoms related to nocturia,” said Carlos Rodriguez, communication manager for Pharmactive. “It also revealed a high percentage of satisfaction among participants. Close to 90% of the users. Nine out of 10 study participants expressed intent to purchase our natural formula and said they would recommend it to others. These findings reinforce the efficacy of Plasys300 and emphasize its potential as a valuable natural solution for men’s urinary health.”
 
“More clinical studies on Plasys300 are in the pipeline,” said Morán Valero. “We are exploring new areas of research toward broadening its applications. As we enhance our understanding of how Plasys300 works, we can further position it as a reliable, science-backed solution for men’s health.”